Trials / Completed
CompletedNCT03193645
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The DUO study's main objective is to evaluate, in the real life, the prevalence of cardiovascular risk in patients with prostate cancer that hormone treatment of androgen suppression by Degarelix was introduced. This study will also assess, at the initiation of therapy, the prevalence of osteoporosis, metabolic comorbidities, depression, sexual and geriatric patients suffering from prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Degarelix | Injection |
Timeline
- Start date
- 2017-06-27
- Primary completion
- 2018-06-30
- Completion
- 2019-01-31
- First posted
- 2017-06-21
- Last updated
- 2019-02-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03193645. Inclusion in this directory is not an endorsement.